Although the molecular target for drug therapy of sickle cell disease has been known for over 50 years, the only drug approved by the United States Food and Drug Administration is hydroxyurea. Hydroxyurea reduces the probability of vaso-occlusion by increasing the synthesis of fetal hemoglobin, which dilutes the abnormal hemoglobin S, markedly slowing its polymerization to form the fibers that distort (sickle) and make the red cells inflexible. This drug is, however, only partially successful in reducing the frequency of pain crises and the chronic organ damage characteristic of the disease. The search for additional and more effective therapeutic agents has been severely hampered by the lack of a relatively high throughput assay for inhibition of sickling. We have developed a method to rapidly, accurately and sensitively test for anti-sickling activity in large populations of human red blood cells by measuring the distribution of sickling times. The first drug screen was carried out on the 2,000 compound library of Microsource Discovery, which contains 800 of the approximately 1,500 of unique compounds contained in the approximatelyy 3,500 FDA-approved drugs. The initial screen was carried out under hyperosmolar conditions. A second screen under iso-osmolar (i.e. physiological) conditions showed time-dependent effects for the most promising compounds. With technical improvements we now can make measurements at physiological osmolarity as a function of both time and concentration, and are re-screening a library of approximately 1,000 FDA approved compounds. The most promising compounds so far are those that reduce intracellular hemoglobin concentration by swelling red cells, taking advantage of the enormous concentration dependence of the delay time. We are are also screening drugs provided by Pfizer, which have been successful in phase I clinical trials, but did not come to market. We are also developing (1) assays to assess the effect of drug binding to plasma proteins, (ii) to test drugs on fractionated SS cells, and (iii) and very high thru-put assay for cell swelling. If the delay time is increased significantly at serum concentrations found for an FDA-approved compound, then, in principle, only two simple additional tests are required before clinical trials could begin, namely the hemolysis test and an oxygen binding curve to insure that the oxygen delivery function of the treated red cells is intact. Both of the assays are now fully developed.
|Cellmer, Troy; Ferrone, Frank A; Eaton, William A (2016) Universality of supersaturation in protein-fiber formation. Nat Struct Mol Biol 23:459-61|
|Boura, Evzen; RÃ³Å¼ycki, Bartosz; Chung, Hoi Sung et al. (2012) Solution structure of the ESCRT-I and -II supercomplex: implications for membrane budding and scission. Structure 20:874-86|
|Chung, Hoi Sung; McHale, Kevin; Louis, John M et al. (2012) Single-molecule fluorescence experiments determine protein folding transition path times. Science 335:981-4|
|Boura, Evzen; RÃ³zycki, Bartosz; Herrick, Dawn Z et al. (2011) Solution structure of the ESCRT-I complex by small-angle X-ray scattering, EPR, and FRET spectroscopy. Proc Natl Acad Sci U S A 108:9437-42|
|Cellmer, Troy; Buscaglia, Marco; Henry, Eric R et al. (2011) Making connections between ultrafast protein folding kinetics and molecular dynamics simulations. Proc Natl Acad Sci U S A 108:6103-8|
|Chung, Hoi Sung; Gopich, Irina V; McHale, Kevin et al. (2010) Extracting Rate Coefficients from Single-Molecule Photon Trajectories and FRET Efficiency Histograms for a Fast-Folding Protein (dagger). J Phys Chem A :|